The estimated Net Worth of Michael F Giordano is at least $208 Tausend dollars as of 25 June 2020. Michael Giordano owns over 19,013 units of Epizyme Inc stock worth over $13,148 and over the last 7 years he sold EPZM stock worth over $0. In addition, he makes $195,162 as Director at Epizyme Inc.
Michael has made over 1 trades of the Epizyme Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 19,013 units of EPZM stock worth $169,596 on 25 June 2020.
The largest trade he's ever made was exercising 19,013 units of Epizyme Inc stock on 25 June 2020 worth over $169,596. On average, Michael trades about 1,358 units every 0 days since 2018. As of 25 June 2020 he still owns at least 8,944 units of Epizyme Inc stock.
You can see the complete history of Michael Giordano stock trades at the bottom of the page.
Dr. Michael F. Giordano M.D. serves as Director of the Company.D. is Director of the Company. Dr. Giordano served as a clinical advisor to us from December 2017 to August 2018. From 1999 to 2017, Dr. Giordano worked at Bristol-Myers Squibb, or BMS, most recently serving as senior vice president and head of development, oncology and immuno-oncology from February 2012 to February 2017. From 1990 to 1999, he served as assistant professor of medicine and founding director of the Cornell Clinical Trials Unit, a National Institutes of Health and Industry-supported AIDS clinical trials center at New York Hospital-Cornell University Medical Center. He earned his M.D. and completed his residency and fellowship training at New York Presbyterian—Weill Cornell Medical Center, and received his B.A. in natural sciences from The Johns Hopkins University.
As the Director of Epizyme Inc, the total compensation of Michael Giordano at Epizyme Inc is $195,162. There are 15 executives at Epizyme Inc getting paid more, with Robert Bazemore having the highest compensation of $4,173,620.
Michael Giordano is 62, he's been the Director of Epizyme Inc since 2018. There are 2 older and 16 younger executives at Epizyme Inc. The oldest executive at Epizyme Inc is Kenneth Bate, 69, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Epizyme Inc have traded over $122,255,844 worth of Epizyme Inc stock and bought 45,285,781 units worth $322,885,823 . The most active insiders traders include Forest Baskett, Scott D Sandell und Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of $394,367. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth $1,704,500.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Epizyme Inc executives and other stock owners filed with the SEC include: